 | | Vol. 10.31 – 9 August, 2022 |
| |
|
|
| Using a high-throughput surface receptor screening method, researchers systematically mapped the direct protein interactions across a recombinant library that encompassed most of the surface proteins that are detectable on human leukocytes.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists revealed a neuroendocrine pathway which suppressed tumor immunity, and suggested MC5R as a potential target for cancer immunotherapy.
[Science] |
|
|
|
| Coupling a stroma-free T cell differentiation system with EZH1-knockdown-mediated epigenetic reprogramming, the authors generated iPSC-derived T cells which displayed a highly diverse T cell receptor repertoire and mature molecular signatures similar to those of TCRαβ T cells from peripheral blood.
[Cell Stem Cell] |
|
|
|
| Investigators showed that the premature expression of the T cell receptor (TCR) or a constitutively expressed CAR in T cell-derived induced pluripotent stem cells promoted the acquisition of an innate phenotype, which could be averted by disabling the TCR and relying on the CAR to drive differentiation.
[Nature Biomedical Engineering] |
|
|
|
| The authors reported a cavity-injectable nanoporter-hydrogel superstructure that created glioma stem cell-specific CAR macrophages/microglia surrounding the cavity to prevent glioblastoma multiforme relapse.
[Science Translational Medicine] |
|
|
|
| Researchers reported the development of an implantable mechanotherapeutic drug delivery platform to mitigate and overcome the host immune response using two distinct, yet synergistic soft robotic strategies.
[Nature Communications] |
|
|
|
| Researchers identified early B cell factor 4 (EBF4), a little-studied member of the EBF family of transcription factors, in a whole-genome CRISPR screen for regulators of Fas/APO-1/CD95-mediated T cell death.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors demonstrate a minimally invasive strategy to locally deliver anti-programmed cell death protein 1 with shear-thinning biomaterials (STBs). Immune checkpoint inhibitors could be injected into tumors when loaded in STBs composed of gelatin and silicate nanoplatelets.
[ACS Applied Materials & interfaces] |
|
|
|
| Investigators showed across multiple human malignancies and syngeneic murine tumor models that neither pretreatment T cell receptor clonality nor changes in clonality after immune checkpoint blockade correlated with response.
[International Journal of Cancer] |
|
|
|
| Scientists reported the preclinical characterization of Tregs transduced with a human leukocyte antigen (HLA)-A*02 CAR lentiviral vector designated to induce immunosuppression of allograft-specific effector T cells in HLA-A*02-negative recipients of HLA-A*02-positive transplants.
[Gene Therapy] |
|
|
|
| Researchers investigated the effect of DJ-1 on helper T cell differentiation, fibroblast-like synoviocyte activation, and osteoclastogenesis in rheumatoid arthritis.
[Scientific Reports] |
|
|
|
| Scientists examined the ability of serum albumin levels and leukocyte subtypes to predict the therapeutic efficacy of tacrolimus in patients with ulcerative colitis.
[Scientific Reports] |
|
|
|
|
| The authors summarize the roles of eextracellular vesicles in basic processes of innate and adaptive immunity, including inflammation, antigen presentation, and the development and activation of B cells and T cells.
[Nature Reviews Immunology] |
|
|
|
| Scientists examine the influence that the gut microbiota have on immune function via modulation of serotonin production in the gut and through complex interactions with components of the immune system, such as T cells and B cells.
[Nature Reviews Neurology] |
|
|
|
|
| Poseida Therapeutics, Inc. announced it has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies.
[Poseida Therapeutics, Inc.] |
|
|
|
| While AstraZeneca may be a major player in the oncology space, the company has been noticeably absent as the first wave of CAR-T therapies hit the market over the past five years. But movement is happening behind the scenes.
[Fierce Biotech] |
|
|
|
| University of Florida (UF) brain cancer researcher Dr. Lan Hoang-Minh has been awarded a $100,000 grant from the St. Baldrick’s Foundation for a preclinical research project seeking to advance adoptive T cell therapy for pediatric brain tumors.
[University of Florida Health] |
|
|
|
|
| October 26 – 29, 2022
Brussels, Belgium |
|
|
|
|
|
| | University of Illinois at Chicago – Chicago, Illinois, United States |
|
|
|
| | Columbia University – New York, New York, United States |
|
|
|
| | Essen University Hospital – Essen, Germany |
|
|
|
| | King’s College London – London, United Kingdom |
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
